Advisor Group Holdings, Inc. Chinook Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$18.66 - $38.58 $5,448 - $11,265	-292 Reduced 24.91%	880 $33,000
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $150 - $187	7 Added 0.6%	1,172 $27,000
Q4 2022 Feb 10, 2023	BUY	$18.63 - $27.35 $3,837 - $5,634	206 Added 21.48%	1,165 $30,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $245 - $327	14 Added 1.48%	959 $19,000
Q1 2022 May 04, 2022	BUY	$12.02 - $16.69 $7,933 - $11,015	660 Added 231.58%	945 $15,000
Q3 2021 Nov 05, 2021	SELL	$11.5 - $14.86 $724 - $936	-63 Reduced 18.1%	285 $4,000
Q2 2021 Aug 02, 2021	BUY	$13.6 - $18.98 $3,848 - $5,371	283 Added 435.38%	348 $5,000
Q4 2020 Feb 10, 2021	BUY	$11.9 - $20.91 $773 - $1,359	65 New	65 $1,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.